Commentary: GSK-3 Inhibition as a Therapeutic Approach Against SARs CoV2: Dual Benefit of Inhibiting Viral Replication While Potentiating the Immune Response
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2020-10-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/article/10.3389/fimmu.2020.595289/full |
| _version_ | 1818878928627957760 |
|---|---|
| author | Andre De Souza Fabio A. Tavora Devalingam Mahalingam Pamela N. Munster Howard P. Safran Wafik S. El-Deiry Wafik S. El-Deiry Benedito A. Carneiro |
| author_facet | Andre De Souza Fabio A. Tavora Devalingam Mahalingam Pamela N. Munster Howard P. Safran Wafik S. El-Deiry Wafik S. El-Deiry Benedito A. Carneiro |
| author_sort | Andre De Souza |
| collection | DOAJ |
| first_indexed | 2024-12-19T14:21:58Z |
| format | Article |
| id | doaj.art-951d7f729e1e41b1b24b7b7d38cb6fd2 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-12-19T14:21:58Z |
| publishDate | 2020-10-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-951d7f729e1e41b1b24b7b7d38cb6fd22022-12-21T20:17:45ZengFrontiers Media S.A.Frontiers in Immunology1664-32242020-10-011110.3389/fimmu.2020.595289595289Commentary: GSK-3 Inhibition as a Therapeutic Approach Against SARs CoV2: Dual Benefit of Inhibiting Viral Replication While Potentiating the Immune ResponseAndre De Souza0Fabio A. Tavora1Devalingam Mahalingam2Pamela N. Munster3Howard P. Safran4Wafik S. El-Deiry5Wafik S. El-Deiry6Benedito A. Carneiro7Division of Hematology/Oncology, Lifespan Cancer Institute, Warren Alpert Medical School of Brown University, Providence, RI, United StatesArgos Laboratory, Fortaleza, BrazilDivision of Hematology/Oncology, Northwestern University, Chicago, IL, United StatesDepartment of Medicine (Hematology/Oncology), Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, United StatesDivision of Hematology/Oncology, Lifespan Cancer Institute, Warren Alpert Medical School of Brown University, Providence, RI, United StatesDivision of Hematology/Oncology, Lifespan Cancer Institute, Warren Alpert Medical School of Brown University, Providence, RI, United StatesDepartment of Pathology and Laboratory Medicine, Alpert Medical School of Brown University, Providence, RI, United StatesDivision of Hematology/Oncology, Lifespan Cancer Institute, Warren Alpert Medical School of Brown University, Providence, RI, United Stateshttps://www.frontiersin.org/article/10.3389/fimmu.2020.595289/fullglycogen synthase kinase-3 (GSK3)glycogen synthase kinase-3 (GSK-3) inhibitorCOVIDCOVID-199-ING-41GSK-3b inhibitor |
| spellingShingle | Andre De Souza Fabio A. Tavora Devalingam Mahalingam Pamela N. Munster Howard P. Safran Wafik S. El-Deiry Wafik S. El-Deiry Benedito A. Carneiro Commentary: GSK-3 Inhibition as a Therapeutic Approach Against SARs CoV2: Dual Benefit of Inhibiting Viral Replication While Potentiating the Immune Response Frontiers in Immunology glycogen synthase kinase-3 (GSK3) glycogen synthase kinase-3 (GSK-3) inhibitor COVID COVID-19 9-ING-41 GSK-3b inhibitor |
| title | Commentary: GSK-3 Inhibition as a Therapeutic Approach Against SARs CoV2: Dual Benefit of Inhibiting Viral Replication While Potentiating the Immune Response |
| title_full | Commentary: GSK-3 Inhibition as a Therapeutic Approach Against SARs CoV2: Dual Benefit of Inhibiting Viral Replication While Potentiating the Immune Response |
| title_fullStr | Commentary: GSK-3 Inhibition as a Therapeutic Approach Against SARs CoV2: Dual Benefit of Inhibiting Viral Replication While Potentiating the Immune Response |
| title_full_unstemmed | Commentary: GSK-3 Inhibition as a Therapeutic Approach Against SARs CoV2: Dual Benefit of Inhibiting Viral Replication While Potentiating the Immune Response |
| title_short | Commentary: GSK-3 Inhibition as a Therapeutic Approach Against SARs CoV2: Dual Benefit of Inhibiting Viral Replication While Potentiating the Immune Response |
| title_sort | commentary gsk 3 inhibition as a therapeutic approach against sars cov2 dual benefit of inhibiting viral replication while potentiating the immune response |
| topic | glycogen synthase kinase-3 (GSK3) glycogen synthase kinase-3 (GSK-3) inhibitor COVID COVID-19 9-ING-41 GSK-3b inhibitor |
| url | https://www.frontiersin.org/article/10.3389/fimmu.2020.595289/full |
| work_keys_str_mv | AT andredesouza commentarygsk3inhibitionasatherapeuticapproachagainstsarscov2dualbenefitofinhibitingviralreplicationwhilepotentiatingtheimmuneresponse AT fabioatavora commentarygsk3inhibitionasatherapeuticapproachagainstsarscov2dualbenefitofinhibitingviralreplicationwhilepotentiatingtheimmuneresponse AT devalingammahalingam commentarygsk3inhibitionasatherapeuticapproachagainstsarscov2dualbenefitofinhibitingviralreplicationwhilepotentiatingtheimmuneresponse AT pamelanmunster commentarygsk3inhibitionasatherapeuticapproachagainstsarscov2dualbenefitofinhibitingviralreplicationwhilepotentiatingtheimmuneresponse AT howardpsafran commentarygsk3inhibitionasatherapeuticapproachagainstsarscov2dualbenefitofinhibitingviralreplicationwhilepotentiatingtheimmuneresponse AT wafikseldeiry commentarygsk3inhibitionasatherapeuticapproachagainstsarscov2dualbenefitofinhibitingviralreplicationwhilepotentiatingtheimmuneresponse AT wafikseldeiry commentarygsk3inhibitionasatherapeuticapproachagainstsarscov2dualbenefitofinhibitingviralreplicationwhilepotentiatingtheimmuneresponse AT beneditoacarneiro commentarygsk3inhibitionasatherapeuticapproachagainstsarscov2dualbenefitofinhibitingviralreplicationwhilepotentiatingtheimmuneresponse |